Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTTXNASDAQ:PIIINASDAQ:REUNNASDAQ:VSEE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTTXBetter Therapeutics$0.00$0.00$0.00▼$0.03$5K1.1919,107 shs203,110 shsPIIIP3 Health Partners$7.15+1.7%$8.45$6.91▼$33.73$51.39M0.9420,310 shs2,305 shsREUNReunion Neuroscience$1.12$1.12$0.63▼$5.07$13.13M2.29210,209 shsN/AVSEEVsee Health$1.18+5.5%$1.16$1.00▼$14.47$4.26MN/A1.04 million shs12,486 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTTXBetter Therapeutics0.00%0.00%-50.00%-50.00%-99.09%PIIIP3 Health Partners-2.09%-3.70%-20.11%-23.21%-71.99%REUNReunion Neuroscience0.00%0.00%0.00%0.00%0.00%VSEEVsee Health-9.66%+2.77%-7.80%-10.38%+112,019,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APIIIP3 Health Partners1.6442 of 5 stars3.32.00.00.01.60.80.6REUNReunion NeuroscienceN/AN/AN/AN/AN/AN/AN/AN/AVSEEVsee Health1.3775 of 5 stars2.03.00.00.02.50.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTTXBetter Therapeutics 0.00N/AN/AN/APIIIP3 Health Partners 2.50Moderate Buy$16.25127.27% UpsideREUNReunion Neuroscience 0.00N/AN/AN/AVSEEVsee Health 4.00Strong Buy$5.00322.98% UpsideCurrent Analyst Ratings BreakdownLatest REUN, PIII, VSEE, and BTTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PIIIP3 Health PartnersLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $20.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/APIIIP3 Health Partners$1.49B0.03$3.08 per share2.32$0.45 per share15.89REUNReunion Neuroscience$3.88M3.38N/AN/A$1.37 per share0.82VSEEVsee Health$6.38M0.67N/AN/A($3.40) per share-0.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTTXBetter Therapeutics-$39.76MN/A0.00∞N/AN/AN/AN/A6/3/2025 (Estimated)PIIIP3 Health Partners-$57.77M-$47.28N/AN/AN/A-6.95%-71.31%-11.93%8/6/2025 (Estimated)REUNReunion Neuroscience-$36.69MN/A0.00N/AN/AN/A-91.82%-64.58%N/AVSEEVsee Health-$4.41MN/A0.00∞N/AN/A-182.59%-58.26%6/5/2025 (Estimated)Latest REUN, PIII, VSEE, and BTTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/5/2025N/AVSEEVsee Health-$0.09-$0.12-$0.03N/A$3.52 million$3.90 million5/15/2025Q1 2025PIIIP3 Health Partners-$5.00-$6.28-$1.28-$6.28$362.09 million$373.23 million3/27/2025Q4 2024PIIIP3 Health Partners-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTTXBetter TherapeuticsN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/AREUNReunion NeuroscienceN/AN/AN/AN/AN/AVSEEVsee HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTTXBetter TherapeuticsN/AN/AN/APIIIP3 Health Partners1.110.530.53REUNReunion NeuroscienceN/A3.513.51VSEEVsee Health0.160.370.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTTXBetter Therapeutics34.00%PIIIP3 Health Partners7.75%REUNReunion Neuroscience12.88%VSEEVsee Health1.01%Insider OwnershipCompanyInsider OwnershipBTTXBetter Therapeutics51.40%PIIIP3 Health Partners17.79%REUNReunion NeuroscienceN/AVSEEVsee Health6.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTTXBetter Therapeutics4049.86 million24.23 millionOptionablePIIIP3 Health Partners5007.19 million294.74 millionNot OptionableREUNReunion Neuroscience1611.72 millionN/ANot OptionableVSEEVsee HealthN/A3.60 million3.37 millionN/AREUN, PIII, VSEE, and BTTX HeadlinesRecent News About These CompaniesVSee Health faces Nasdaq compliance issue over late filingsJune 1 at 5:17 PM | investing.comVSee Health faces Nasdaq delisting over late filingJune 1 at 5:17 PM | uk.investing.comVSee Health, Inc. Receives Nasdaq Notice on Delayed Form 10-Q FilingMay 30, 2025 | businesswire.comContrasting Vsee Health (NASDAQ:VSEE) & DCC (OTCMKTS:DCCPF)May 24, 2025 | americanbankingnews.comVSee Health launches telehealth initiative in the PhilippinesMay 17, 2025 | investing.comVSee Health Launches AI-Powered Telehealth to Reduce Maternal Deaths in Remote PhilippinesMay 16, 2025 | businesswire.comVSee Health, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K FilingMay 12, 2025 | businesswire.comVSee Health Inc. Faces Nasdaq Delisting Over Late FilingMay 10, 2025 | investing.comVSee Health unveils AI-driven telenursing platformApril 18, 2025 | uk.investing.comVSee Unveils Advanced Telenursing Robotics Solution Targeting 3-5% Reduction in Hospital Nursing CostsApril 16, 2025 | finance.yahoo.comVSee Health Highlights: AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare Market Featured Image featured image Admin MessageApril 2, 2025 | markets.businessinsider.comVSee Health Highlights: AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare MarketApril 2, 2025 | prnewswire.comVSee Health issues letter to shareholders updating progressMarch 7, 2025 | markets.businessinsider.comVSee Issues Shareholder Letter Highlighting 2024 Achievements and Strong Growth Outlook for 2025March 6, 2025 | finance.yahoo.comVSee Health wins telehealth contract for mental health servicesMarch 6, 2025 | finance.yahoo.comVSee Health Secures $444K County Government Contract, Expanding Market Reach in Public Sector HealthcareMarch 5, 2025 | finance.yahoo.comVSee Health and LanguageLine Team Up to Boost Telehealth Adoption with Seamless, Scalable Multilingual CareFebruary 25, 2025 | finance.yahoo.comVSee Health and LanguageLine Team Up to Boost Telehealth Adoption with Seamless, Scalable Multilingual CareFebruary 25, 2025 | businesswire.comMaxim Group Initiates Coverage of VSee Health (VSEE) with Buy RecommendationFebruary 25, 2025 | msn.comVSee Health initiated with a Buy at MaximFebruary 24, 2025 | markets.businessinsider.comMedia Sentiment Over TimeREUN, PIII, VSEE, and BTTX Company DescriptionsBetter Therapeutics NASDAQ:BTTX$0.0001 0.00 (0.00%) As of 06/2/2025 10:57 AM EasternBetter Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.P3 Health Partners NASDAQ:PIII$7.15 +0.12 (+1.71%) As of 12:21 PM EasternP3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.Reunion Neuroscience NASDAQ:REUNReunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.Vsee Health NASDAQ:VSEE$1.18 +0.06 (+5.53%) As of 12:06 PM EasternVSee Health, Inc. is a no-code or low-code software as a service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. It engages in providing timely, quality healthcare to patients regardless of geographical barriers. The company is headquartered in Boca Raton, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Steel Dynamics Shares Climb After Tariff Announcement Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
